Intravenous immunoglobulins and granulocyte colony-stimulating factor for the management of infection in intensive care units

Current Opinion in Critical Care

Volumn 3, Issue 5, 1997, Pages 342-347

  Zanetti, Giorgio ^a   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001454671     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Pittet D, Wenzel RP: Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995, 155:1177-1184.
2. Bryan CS, Reynold KL, Brenner ER: Analysis of 1186 episodes of Gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983, 5:629-638.
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995, 273:117-123.
4. Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in critically III patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994, 271:1598-1601.
5. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982, 307:1225-1230.
6. Calandra T, Glauser MP, Schellekens J, Verhoef J, Swiss-Dutch J5 Immunoglobulin Study Group: Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized study. J Infect Dis 1988, 156:312-319.
7. Cohen J, Heumann D, Glauser MP: Do monoclonal antibodies and anti-cytokines still have a future in infectious diseases? Am J Med 1995, 99:45S-52S.
8. Grob P, Holch M, Fierz W: Immunodeficiency after major trauma and selective surgery. Pediatr Infect Dis 1988, 7:S37-S42.
9. Mc Ritchie DI, Girotti MJ, Rotstein OD, Teodorczyk-Injeyan JA: Impaired antibody production in blunt trauma. Arch Surg 1990, 125:91-96.
10. Moran K, Munster AM: Alterations of the host defense mechanisms in burned patients. Surg Clin North Am 1987, 67:47-56.
11. McGowan JEJ, Barnes WN, Finland MB: Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972) with special reference to hospital-acquired cases. J Infect Dis 1975, 132:326-341.
12. Ferrera JJ, Peterson RD, Hester R: Inhibition of lymphocyte blastogenesis caused by suppression of interleukin-2 receptor sites after thermal injury. J Burn Care Rehabil 1989, 10:119-124.
13. Faist E, Mewes A, Strasser T: Alterations of cell-mediated immune response following cardiac surgery. Arch Surg 1988, 123:287-292.
14. Markevitz A, Faist E, Weinhold C: Alterations of cell-mediated immune response following cardiac surgery. Eur J Cardiothorac Surg 1993, 7:193-199.
15. Wakefield CH, Carey PD, Foulds S: Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993, 80:205-209.
16. Pilz G, Appel R, Kreuzer E, Werdan K: Comparison of early IgM-enriched immunoglobulin vs polyvalent IgQ administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 1997, 111:419-426.
17. Zanetti G, Glauser MP, Baumgartner JD: Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 1991, 13:985-992.
18. Cometta A, Baumgartner JD, Glauser MP: Polyclonal intravenous immune globulin for prevention and treatment of Infections in critically ill patients. Clin Exp Immunol 1994, 97:69-72.
19. The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993, 269:390-391.
20. Cone LA, Woodward DR, Schlievert PM, Tomory GS: Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987, 317:146-149.
21. Stevens DL, Tanner MH, Winship J, Sworts R, Ries KM, Schlievert PM, Kaplan E: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin. N Engl J Med 1989, 321:1-8.
22. Demers B, Simor AE, Velland P, Schlievert PM, Byrne S, Jamieson F, Welmsley S, Low DE: Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993, 16:792-800.
23. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, Low DE, Ontario Group A Streptococcal Study group: Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996, 335:547-554.
24. Schlievert PM, Assimacopoulos AP, Cleary PP: Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J Lab Clin Med 1996, 127:13-22. This is an outstanding review on streptococcal toxic shock syndrome, with emphasis on its epidemiology and physiopathology.
25. Takei A, Arora YK, Walker SM: Intravenous immunoglobulin contains antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1992, 91:602-607.
26. Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, Cohen IR, Lider O. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease: upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 1994, 93:600-605.
27. Nadal D, Lauener RP, Braegger CP, Kaufhold A, Simma B, Lutticken R, Seger RA: T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr 1993, 22:727-729.
28. Stevens DL: The toxic shock syndrome. Infect Dis Clin North Am 1996, 10:727-746.
29. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude JV: Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal Infections: case report and review. Clin Infect Dis 1995, 21:1469-1470.
30. Barry W, Hudgins L, Donta ST, Pesanti EL: Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315-3316.
31. Yong MJ: Necrotizing fasciitis [letter]. Lancer 1994, 343:1427.
32. Kaul R, McGeer A, Ontario Streptococcal Study Group, Norrby-Teglund A, Kotb M, Low DE: Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome: results of a matched case-control study, abstr. LM68. Abstracts of the 35th interscience Conference of Antimicrobial Agents and Chemotherapy, American Society for Microbiology September 1995:339.
33. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, Andersson U, Kotb M: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996, 156:3057-3064. Together with the study by Norrby-Teglund et al. (Infect Immun 1996, 64:5395-5398), this paper provides important experimental arguments for a beneficial role of IVIG in the treatment of invasive GAS infections.
34. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, Andersson U, Kotb M: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996, 156:3057-3064. Together with the study by Norrby-Teglund et al. (Infect Immun 1996, 64:5395-5398), this paper provides important experimental arguments for a beneficial role of IVIG in the treatment of invasive GAS infections.
35. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, Kotb M: Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996, 64:5395-5398. Together with the study by Norrby-Teglund et al. (J Immunol 1996, 156:3057-3064), this paper provides experimental arguments for a beneficial role of IVIG in the treatment of invasive GAS infections.
36. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, Kotb M: Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996, 64:5395-5398. Together with the study by Norrby-Teglund et al. (J Immunol 1996, 156:3057-3064), this paper provides experimental arguments for a beneficial role of IVIG in the treatment of invasive GAS infections.
37. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK: Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986, 232:61-65.
38. Nelson S, Bagby GJ: Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Clin Chest Med 1996, 17:319-332.
39. Lee A, Whyte MK, Haslett C: Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993, 54:283-288.
40. Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, Wernet P: Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 1995, 10:21-26.
41. Simms HH, D'Amico R: Granulocyte colony-stimulating factor reverses septic shock-induced polymorphonuclear leukocyte dysfunction. Surgery 1994, 115:85-93.
42. Goya T, Torisu M, Doi F, Yoshida T: Effects of granulocyte colony stimulating factor and monobactam antibiotics (aztreonam) on neutrophil functions in sepsis. Clin Immunol Immunopathol 1993, 69:278-284.
43. Nelson S: The effects of thermal injury on systemic and pulmonary host defenses. Crit Care Rep 1991, 2:241-246.
44. Wilson NW, Wu YP, Peterson B, Bastian JF: Immunoglobulins and IgG subclasses in children following severe head injury. Intensive Care Med 1994, 20:508-510.
45. Inoue T, Obata M, Mishima Y: Polymorphonuclear leukocyte function and serum opsonic activity in surgical patients. Surg Today 1992, 22:233-243.
46. Saito T, Kuwahara A, Shimoda K, Kinoshita T, Shigemitsu Y, Miyahara M, Kobayashi M: Enhanced Immunoglobulin levels correlate with infectious complications after surgery in esophageal cancer. J Surg Oncol 1991, 46:3-8.
47. Christou NV, Tellado JM: In vitro polymorphonuclear neutrophil function in surgical patients does not correlate with energy but with "activating" processes such as sepsis or trauma. Surgery 1989, 106:718-722.
48. Silver GM, Gamelli RL, O'Reilly M: The beneficial effect of granulocyte colony-stimulating factor (G-CSF) in combination with gentamicin on survival after Pseudomonas burn wound infection. Surgery 1989, 106:452-455.
49. Mooney DP, Garnelli RL, O'Reilly M, Hebert JC: Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis. Arch Surg 1988, 123:1353-1357.
50. O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC: Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992, 33:679-682.
51. Nelson S, Summer W, Bagby G, Nakamura C, Stewart L, Lipscomb G, Andresen J: Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991, 164:901-906.
52. Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995, 86:1301-1309.
53. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A: Control of fecal peritoneal infection in mice by colony-stimulating factors. J Infect Dis 1996, 174:790-799. The authors describe the effects of both suppression of endogenous G-CSF and administration of exogenous G-CSF in a clinically relevant model of intra-abdominal infection.
54. Lundblad R, Nesland JM, Giercksky KE: Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med 1996, 24:820-826.
55. Heidenreich S, Gong JH, Schmidt A, Nain M, Gemsa D: Macrophage activation by granulocyte/macrophage colony-stimulating factor: priming for enhanced release of tumor necrosis factor-alpha and prostaglandin E2. J Immunol 1989, 143:1198-1205.
56. Antman KS, Griffin JD, Elias A: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988, 319:593-597.
57. Tiegs G, Barsig J, Matiba B, Uhlig S, Wendel A: Potentlation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J Clin Invest 1994, 93:2616-2622.
58. Toda H, Murata A, Oka Y, Uda K, Tanaka N, Ohashi I, Mori T, Matsuura N: Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood 1994, 83:2893-2898.
59. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD: Human granulocyte-monocyte colony-stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988, 71:672-676.
60. Goergen I, Hartung T, Leist M: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 1992, 149:918-924.
61. Terashima T, Soejima K, Waki Y: Neutrophils activated by granulocyte colony-stimulating factor suppress tumor necrosis factor-α release from monocytes stimulated by endotoxin. Am J Respir Cell Mol Biol 1995, 13:69-73.
62. Hartung T, Doecke WD, Gantner F: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995, 85:2482-2489.
63. Hartung T, Volk HD, Wendel A: G-CSF, an anti-inflammatory cytokine. J Endotoxin Res 1995, 2:195-201.
64. Freeman BD, Correa R, Karzai W, Natanson C, Patterson M, Banks S, Fitz Y, Danner RL, Wilson L, Eichacker PQ: Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 1996, 80:2066-2076.
65. Pollmächar T, Korth C, Mullington J, Schreiber W, Sauer J, Vedder H, Galanos C, Holsboer F: Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996, 87:900-905.
66. Duswald KH, Müller K, Seifert J, Ring J: Wirksamkeit von i.v. Gammagtobulin gegen bakterielle infektionen chirurgischer Patienten. Muench Med Wochenschr 1980, 122:832-836.
67. Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A: Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma: a randomized, placebo-controlled study. Intensive Care Med 1985, 11:288-294.
68. The Intravenous Immunglobulin Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992, 327:234-240.
69. Cafiero F, Gipponi M, Bonalumi U, Piccardo A, Sguotti C, Corbetta G: Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial. Surgery 1992, 112:24-31.
70. Munster AM, Moran KT, Thupari J, Allo M, Winchurch RA: Prophylactic intravenous immunoglobulin in high-risk burn patients. J Burn Care Rehabil 1987, 8:376-380.
71. Waymack JP, Jenkins ME, Alexander JW, Warden GD, Miller AC, Carey M, Ogle CK, Kopcha RG: A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. Burns 1989, 15:71-76.
72. Just HM, Metzger M, Vogel W, Pelka R: Einfluss einer adjuvanten immunoglobulintherapie auf infectionen bei Patienten einer operativen Intensiv-Therapie-Station. Klinn Wochenschr 1986, 64:245-256.
73. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J, Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 1987, 65:1132-1138.
74. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Acquarolo A, Ballabio A, Sguotti C: Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991, 126:236-240.
75. Pilz G, Kruezer E, Kaabs S, Appel R, Werdan K: Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 1994, 105:76-82.
76. Dale DC, Liles WC, Summer WR, Nelson S: Granulocyte colony-stimulating factor: role and relationships in infectious diseases. J Infect Dis 1995, 172:1061-1075.